Canagliflozin audit examines ‘real life benefits’
An audit to compare the drug Canagliflozin in clinical trials with real life outcomes has been launched.
The aim of the Canagliflozin Audit is to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials, the Association of British Clinical Diabetologists (ABCD) said.
Clinicians using Canagliflozin have been invited to submit the data they routinely collect when monitoring the progress of their patients, including HbA1c levels, weight and side effects.
It is hoped the audit, which was launched at a meeting at the Royal College of Physicians, will gain insight into both the safety and efficacy of Canagliflozin. The data will also inform future practice and guidelines.
It will also be used to quantify and analyse other factors including how much HbA1c reduction occurs with Canagliflozin in real clinical use and whether the reduction is durable over time in the real world.
The audit has a number of objectives, which include what impact the drug has on blood pressure and what is the impact on lipids.
To enable a more efficient way of gathering the data a web-based audit tool has been created which is being hosted on N3, the latest version of NHSnet.
The tool is similar to the one which has been used for the Dapagliflozin Audit and helps make the comparison between both audits a much easier task, as well as combining the data for analysis of class.
It has optimum security for patient identity, but the data is made anonymous when utilised in the national audit.